Redhill to Start Phase III Trial of Antibiotic Therapy in Crohn's
The controversial theory that infection with Mycobacterium avium subspecies paratuberculosis (MAP) is a causative agent in Crohn's disease is about to receive its biggest test yet, as Redhill Biopharma Ltd. initiates a Phase III program involving RHB-104, an antibiotic treatment, in some 600 patients.
Suite: 1100 | Atlanta, Georgia 30346, USA
Outside of the US
In the U.S. and Canada: +1-877-857-2477
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
Sign up for Highlights FREE e-mail newsletter